ATAD3A and neoplasm: These results suggest that paclitaxel upregulates ATAD3A and reduces PINK1-mediated mitophagy to disrupt PD-L1 proteostasis by blocking an intrinsic degradation pathway and facilitating high level accumulation, resulting in a severely immunosuppressed tumor microenvironment that causes failure of immunotherapy.